Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2023 | Immune-related AEs in patients with breast cancer treated with IO

Neelima Vidula • 6 Dec 2023
SABCS 2023
Breast Cancer Antibodies Atezolizumab Pembrolizumab
IMpassion130 KEYNOTE-355 KEYNOTE-522

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, discusses a real-world study to understand the toxicity of immunotherapy (IO) and immune-related adverse events (irAEs) in patients with breast cancer ≥65 years treated with pembrolizumab or atezolizumab. The aim of this retrospective review was to help inform clinical decision making in this patient population. In this patient cohort, similar overall rates of irAEs were observed in patients ≥65 years and less than 65 years. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Neelima Vidula

Phase II trial of talazoparib in HER- breast cancer with somatic BRCA1/2 mutations
1:58
Phase II trial of talazoparib in HER- breast cancer with somatic BRCA1/2 mutations
Neelima Vidula • 13 Dec 2024
Evaluating organ-specific responses to ADCs in metastatic breast cancer
2:06
Evaluating organ-specific responses to ADCs in metastatic breast cancer
Neelima Vidula • 13 Dec 2024
Age-specific variations in irAEs on IO
1:09
Age-specific variations in irAEs on IO
Neelima Vidula • 6 Dec 2023
Impact of race on clinical, socioeconomic, genomic characteristics among patients with MBC
4:12
Impact of race on clinical, socioeconomic, genomic characteristics among patients with MBC
Neelima Vidula • 7 Dec 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals